Ricardos Ghanem, Sylvie Glaisner, Arthur Bobin, Anne-Marie Ronchetti, Sophie Cereja, Bertrand Joly, Célia Salanoubat, Guillemette Fouquet
Posterior reversible encephalopathy syndrome (PRES) has rarely been described in myeloma, but chemotherapy is a known risk factor. We report 3 patients with myeloma who developed PRES, and analyzed them with 13 published cases, mostly women. The most frequent causative agents were proteasome inhibitors and autologous stem cell transplantation. Risk factors were frequently associated: hypertension, infection or renal failure. Symptoms included headache, blurred vision, altered mental status, seizures. Most patients experienced rapid clinical recovery, without relapse even after resuming treatment...
2024: Leukemia Research Reports